PBPK model reporting template for chemical risk assessment applications.

Documentation Harmonized report Pharmacokinetics Physiologically-based pharmacokinetic (PBPK) model Regulatory review Regulatory risk assessment Regulatory submission Reporting template Standardized report

Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 03 03 2020
revised: 18 05 2020
accepted: 28 05 2020
pubmed: 6 6 2020
medline: 26 3 2021
entrez: 6 6 2020
Statut: ppublish

Résumé

Physiologically-based pharmacokinetic (PBPK) modeling analysis does not stand on its own for regulatory purposes but is a robust tool to support drug/chemical safety assessment. While the development of PBPK models have grown steadily since their emergence, only a handful of models have been accepted to support regulatory purposes due to obstacles such as the lack of a standardized template for reporting PBPK analysis. Here, we expand the existing guidances designed for pharmaceutical applications by recommending additional elements that are relevant to environmental chemicals. This harmonized reporting template can be adopted and customized by public health agencies receiving PBPK model submission, and it can also serve as general guidance for submitting PBPK-related studies for publication in journals or other modeling sharing purposes. The current effort represents one of several ongoing collaborations among the PBPK modeling and risk assessment communities to promote, when appropriate, incorporating PBPK modeling to characterize the influence of pharmacokinetics on safety decisions made by regulatory agencies.

Identifiants

pubmed: 32502513
pii: S0273-2300(20)30117-3
doi: 10.1016/j.yrtph.2020.104691
pmc: PMC8188465
mid: NIHMS1700380
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104691

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Drug Metab Dispos. 2015 Nov;43(11):1823-37
pubmed: 26296709
Toxicol Lett. 2007 Mar 30;169(3):222-35
pubmed: 17336003
Toxicol Appl Pharmacol. 2013 Dec 15;273(3):464-76
pubmed: 23732079
Am J Physiol. 1980 Jul;239(1):R7-24
pubmed: 7396041
Clin Pharmacokinet. 2014 Mar;53(3):283-293
pubmed: 24214317
Chemosphere. 2017 Oct;184:1194-1201
pubmed: 28672700
J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):591-609
pubmed: 26194069
Integr Biol (Camb). 2015 Apr;7(4):383-91
pubmed: 25739725
Clin Pharmacol Ther. 2011 Feb;89(2):259-67
pubmed: 21191381
J Toxicol Environ Health A. 2006 Sep;69(18):1727-56
pubmed: 16864423
Toxicol Appl Pharmacol. 2017 May 1;322:27-40
pubmed: 28237878
J Pharm Sci. 2017 Sep;106(9):2380-2391
pubmed: 28456730
Risk Anal. 2004 Dec;24(6):1697-717
pubmed: 15660623
Curr Pharmacol Rep. 2016;2:161-169
pubmed: 27226953
J Pharmacokinet Pharmacodyn. 2017 Jun;44(3):277-290
pubmed: 28260166
J Appl Toxicol. 2016 Sep;36(9):1095-111
pubmed: 26649444
Toxicol Sci. 2012 Mar;126(1):5-15
pubmed: 22045031
Clin Pharmacokinet. 2017 Apr;56(4):383-394
pubmed: 27596256
Environ Pollut. 2012 Apr;163:134-41
pubmed: 22325441
Ann ICRP. 2002;32(3-4):5-265
pubmed: 14506981
Toxicol Sci. 2018 Apr 1;162(2):341-348
pubmed: 29385573
Toxicol Sci. 2014 Nov;142(1):210-24
pubmed: 25145659
Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):689-705
pubmed: 27858342
Regul Toxicol Pharmacol. 2015 Dec;73(3):689-98
pubmed: 26545325
Regul Toxicol Pharmacol. 2017 Nov;90:104-115
pubmed: 28866268
Curr Pharm Des. 2015;21(39):5688-98
pubmed: 26323410
Toxicology. 2010 Dec 30;278(3):256-67
pubmed: 20600548
CPT Pharmacometrics Syst Pharmacol. 2015 Apr;4(4):226-30
pubmed: 26225246
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
J Toxicol. 2012;2012:852384
pubmed: 22899915
Clin Pharmacol Ther. 2018 Jul;104(1):88-110
pubmed: 29315504
Front Pharmacol. 2011 Jun 23;2:31
pubmed: 21772819
Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84
pubmed: 9249929
Regul Toxicol Pharmacol. 2010 Jun;57(1):103-16
pubmed: 20122977
Sci Total Environ. 2016 Oct 15;568:785-793
pubmed: 27102273
Environ Health Perspect. 2015 Dec;123(12):1317-24
pubmed: 26008903
Regul Toxicol Pharmacol. 2013 Jun;66(1):116-29
pubmed: 23535119
Toxicol Appl Pharmacol. 1987 Feb;87(2):185-205
pubmed: 3824380
Environ Health Perspect. 2000 Oct;108 Suppl 5:883-93
pubmed: 11035998
Toxicol Sci. 2007 Oct;99(2):395-402
pubmed: 17483121
J Appl Toxicol. 2007 May-Jun;27(3):218-37
pubmed: 17299829
Drug Metab Dispos. 2015 Oct;43(10):1417-29
pubmed: 26180127

Auteurs

Yu-Mei Tan (YM)

U.S. Environmental Protection Agency, Office of Pesticide Programs, Health Effects Division, 109 TW Alexander Dr, Research Triangle Park, NC, 27709, USA. Electronic address: tan.cecilia@epa.gov.

Melissa Chan (M)

Corteva Agriscience, Haskell R&D Center, 1090 Elkton Road, Newark, DE, 19714, USA. Electronic address: melissa.chan@corteva.com.

Amechi Chukwudebe (A)

BASF Corporation, 26 Davis Drive, Research Triangle Park, NC, 27709, USA. Electronic address: amechi.chukwudebe@basf.com.

Jeanne Domoradzki (J)

Corteva Agriscience, Haskell R&D Center, 1090 Elkton Road, Newark, DE, 19714, USA.

Jeffrey Fisher (J)

National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd, Jefferson, AR, 72079, USA. Electronic address: Jeffrey.Fisher@fda.hhs.gov.

C Eric Hack (CE)

ScitoVation, 100 Capitola Drive, Durham, NC, 27713, USA. Electronic address: ehack@scitovation.com.

Paul Hinderliter (P)

Syngenta Crop Protection, LLC, 410 Swing Rd, Greensboro, NC, 27409, USA. Electronic address: paul.hinderliter@alexion.com.

Kota Hirasawa (K)

Sumitomo Chemical Co, Ltd, 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka, 554-8558, Japan. Electronic address: hirasawak@sc.sumitomo-chem.co.jp.

Jeremy Leonard (J)

Oak Ridge Institute for Science and Education, 100 ORAU Way, Oak Ridge, TN, 37830, USA. Electronic address: Leonard.Jeremy@epa.gov.

Annie Lumen (A)

National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd, Jefferson, AR, 72079, USA. Electronic address: Annie.Lumen@fda.hhs.gov.

Alicia Paini (A)

European Commission Joint Research Centre, Via E. Fermi 2749, Ispra I, 21027, Italy. Electronic address: alicia.paini@ec.europa.eu.

Hua Qian (H)

ExxonMobil Biomedical Sciences, Inc, 1545 US Hwy 22 East, Annandale, NJ, 08801, USA. Electronic address: hua.qian@exxonmobil.com.

Patricia Ruiz (P)

CDC-ATSDR, 4770 Buford Hwy, Mailstop S102-1, Chamblee, GA, 3034, USA. Electronic address: pruiz@cdc.gov.

John Wambaugh (J)

US Environmental Protection Agency, Center for Computational Toxicology and Exposure, 109 TW Alexander Dr, Research Triangle Park, NC, 27711, USA. Electronic address: wambaugh.john@epa.gov.

Fagen Zhang (F)

The Dow Chemical Company, 1803 Building, Midland, MI, 48674, USA. Electronic address: FZZhang@dow.com.

Michelle Embry (M)

Health and Environmental Sciences Institute, 740 15th Street, NW, Suite 600, Washington, DC, 20005, USA. Electronic address: membry@hesiglobal.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH